Field safety corrective action and medical device recalls: the US, EU and UK rules
A field safety corrective action (FSCA) is what a device maker does to reduce the risk of a serious incident from a device already on the market: a recall, a modification, a software update or new advice to users. The EU and Great Britain use that name. US law calls these actions corrections and removals, and the US Food and Drug Administration (FDA) calls one a recall when it considers the device in breach of the law it administers and would take legal action over it, such as seizure.
This guide quotes each market’s trigger, deadline, report and notice from the official text, with what to do and the evidence to keep. All three ask for a report to the regulator and a notice to the people who use the device, each with its own deadline. The EU and Great Britain want the report before the action starts, unless it is urgent. The US wants it within 10 working days of the start. So one procedure can serve all three markets: prepare the report and the notice before you act, then file each market’s report by its own deadline.
Field safety corrective actions and recalls: the rules in brief
- In the EU and Great Britain, a maker reports an FSCA to the regulator before taking it, unless the action is urgent, and sends the device’s users a field safety notice.
- In the US, a maker or importer reports a correction or removal within 10 working days of starting it, when it starts the action to reduce a risk to health or to remedy a violation that may present one.
- The FDA classes each recall as class I, II or III by its health hazard. Class I and II recalls need the report; for class III, a record is enough.
- In the EU today, makers report FSCAs through the national vigilance system of each member state concerned, on the current FSCA form. EUDAMED, the European database on medical devices, takes these reports once its vigilance module is mandatory; that module is still in development.
- Great Britain’s rules changed in June 2025. The draft field safety notice now goes to the Medicines and Healthcare products Regulatory Agency (MHRA) before customers see it, and the notice must carry device identifiers in a format people can search.
- In all three markets, the notice identifies the devices, explains the risk and tells users what to do.
- Missing a report carries legal risk in each market: in the US it makes the device misbranded (21 U.S.C. 352(t)), the EU leaves penalties to each member state (Article 113), and Great Britain enforces its rules through the Consumer Protection Act 1987 (regulation 61(1)).
What counts as a field safety corrective action or a recall
The EU Medical Device Regulation, Regulation (EU) 2017/745, defines the term:
‘field safety corrective action’ means corrective action taken by a manufacturer for technical or medical reasons to prevent or reduce the risk of a serious incident in relation to a device made available on the market;
A serious incident is one that “directly or indirectly led, might have led or might lead to” a death, a serious deterioration in someone’s health or a serious public health threat (Article 2(65)). A field safety notice (FSN) is “a communication sent by a manufacturer to users or customers in relation to a field safety corrective action” (Article 2(69)). The regulation also defines a recall, “any measure aimed at achieving the return of a device that has already been made available to the end user” (Article 2(62)), and a withdrawal, “any measure aimed at preventing a device in the supply chain from being further made available on the market” (Article 2(63)).
Great Britain’s Medical Devices Regulations 2002 use almost the same words: “a corrective action taken by the manufacturer to prevent or reduce the risk of a serious incident in relation to a device which has already been placed on the market or put into service” (regulation 44ZC). The same regulation says a corrective action “may include recalling the device, withdrawing it from the market, and taking it out of service”.
The MHRA’s vigilance guidance lists examples of FSCAs: a recall, an inspection, a modification or software update, a calibration update for in vitro diagnostic devices, new or highlighted guidance in the instructions for use, and advice on following up patients or users.
US law names two kinds of action. A correction is “the repair, modification, adjustment, relabeling, destruction, or inspection (including patient monitoring) of a device without its physical removal from its point of use to some other location” (21 CFR 806.2(d)). A removal takes the device away for the same purposes (806.2(j)). A recall is a correction or removal of a product the agency considers in breach of the law:
Recall means a firm’s removal or correction of a marketed product that the Food and Drug Administration considers to be in violation of the laws it administers and against which the agency would initiate legal action, e.g., seizure. Recall does not include a market withdrawal or a stock recovery.
Part 806 exempts four kinds of action from the report: an improvement that reduces no risk to health and remedies no violation, a market withdrawal, routine servicing and a stock recovery (806.1(b)). A market withdrawal involves “a minor violation of the act that would not be subject to legal action by FDA or that involves no violation of the act” (806.2(i)). The agency’s page on recalls, corrections and removals adds: “A report must be made even if the event was caused by use error.”
What to do. For each action on devices already in the field, write down the problem, whether it could lead to a serious incident or a risk to health, and which definition it meets in each market where you sell the device.
Evidence to keep. That decision record, with the health hazard evaluation behind it, for every field action, including the ones you decide not to report.
When to report: the deadlines in the US, the EU and Great Britain
Every deadline side by side
| US | EU | Great Britain | |
|---|---|---|---|
| Who reports | The manufacturer or importer that starts the action | The manufacturer | The manufacturer; its UK responsible person may submit the report |
| What needs a report | A correction or removal started to reduce a risk to health, or to remedy a violation that may present one | Any FSCA for a device on the EU market, including one taken outside the EU unless its reason is limited to the device there | Any FSCA for a device placed on the market or put into service in Great Britain since Part 4A came into force |
| Before the action | No report; notify the FDA of a recall when you start it (7.46(a), guidance) | The report and the draft notice, without undue delay (Articles 87(8) and 89(8)) | Produce a risk assessment, then send the initial report and the draft notice (44ZJ(1)) |
| Comments on the draft notice | No comment period in Part 806 | Allow 48 hours, two weekdays (MDCG 2023-3 Rev.2) | Wait 5 working days; the MHRA’s two pages say “5 days” and “5 working days” |
| If the action is urgent | No exception: the 10 working days still run from the start | Act first, then report (Article 87(8)) | Act first, then report (44ZJ(4)) |
| After the action starts | The report within 10 working days; an amendment within 10 working days of extending the action (806.10(b) and (d)) | The authority evaluates the action (Article 89(3)) | Carry out the action as soon as possible and monitor its progress (44ZJ(3)) |
| During the action | Status reports, generally every 2 to 4 weeks (7.53(a), guidance) | No period set in Articles 87 and 89 | Risk assessment and evidence of progress within 3 working days of a request (44ZJ(8)) |
| Closing | The FDA ends the recall when the action has worked (7.55, guidance) | Articles 87 and 89 set none; the current FSCA form has a “Final report” type | A final report with evidence that the action worked (44ZJ(7)) |
| An action in another country | No separate rule in Part 806 | Report it before the action (Article 87(8)), unless its reason is limited to the device there (Article 87(1)(b)) | Report it within 3 UK working days of its notice going out, if you do not take the same action in Great Britain (44ZK; MHRA guidance) |
| Where the report goes | The FDA, by email to a division recall coordinator or through eSubmitter | The national vigilance system of each member state concerned; EUDAMED once its vigilance module is mandatory | The MHRA, through MORE |
The US: 21 CFR Part 806 and the recall guidance in Part 7
Each device manufacturer or importer shall submit a written report to FDA of any correction or removal of a device initiated by such manufacturer or importer if the correction or removal was initiated: (1) To reduce a risk to health posed by the device; or (2) To remedy a violation of the act caused by the device which may present a risk to health unless the information has already been provided as set forth in paragraph (f) of this section or the corrective or removal action is exempt from the reporting requirements under § 806.1(b).
Paragraph (f) covers an action already reported under Part 803, the medical device reporting rule, or Part 1004, on electronic products. The deadline:
The manufacturer or importer shall submit any report required by paragraph (a) of this section within 10-working days of initiating such correction or removal.
The “risk to health” of 806.2(k) matches the FDA’s class I and class II recalls, and the agency’s page says: “reports of corrections and removals are required for Class I and Class II recalls.” For class III, “only record keeping requirements would apply”. The same page says: “Only the person that initiates the correction or removal is required to report.”
If you extend the action to more lots or batches, you amend the report “within 10-working days of initiating the extension of the correction or removal” (806.10(d)). Part 806 has no exception for urgent actions: the 10 working days run from the start. The agency takes the report by email to its division recall coordinator or through its eSubmitter software.
Part 7 of Title 21 sets the FDA’s recall guidance. A firm that removes or corrects a product because it believes the product unlawful “is requested to notify immediately the appropriate Food and Drug Administration district office”. The agency may then ask for the facts that section lists, from the product’s identity and the reason for the action to the proposed recall strategy and a contact, before it assigns the recall a class and lists it in its weekly Enforcement Report (7.46(a) and (b)). The class follows a health hazard evaluation, which weighs factors such as “Whether any disease or injuries have already occurred from the use of the product”, the likelihood of the hazard and its consequences (7.41(a)). For a recall it starts, the firm develops a recall strategy (7.42(a)), which sets the depth of the recall, whether to warn the public and the effectiveness checks (7.42(b)).
What to do. Run every correction or removal through a Part 806 check on the day you decide to act. Report each one started to reduce a risk to health, or to remedy a violation that may present one, within 10 working days, unless you have already reported it under Part 803 or Part 1004 or it falls under 806.1(b). Notify the agency of a recall when you start it, with your health hazard evaluation and recall strategy.
Evidence to keep. Each Part 806 report and amendment, with the date you started the action and the date you filed; the health hazard evaluation and the recall strategy.
The EU: Articles 87 and 89 of the Medical Device Regulation
Article 87(1) requires makers of devices on the EU market to report to “the relevant competent authorities”, among other things:
any field safety corrective action in respect of devices made available on the Union market, including any field safety corrective action undertaken in a third country in relation to a device which is also legally made available on the Union market, if the reason for the field safety corrective action is not limited to the device made available in the third country.
The report comes first:
Except in cases of urgency in which the manufacturer needs to undertake field safety corrective action immediately, the manufacturer shall, without undue delay, report the field safety corrective action referred to in point (b) of paragraph 1 in advance of the field safety corrective action being undertaken.
The draft notice goes to the authority too: “Except in cases of urgency, the content of the draft field safety notice shall be submitted to the evaluating competent authority or, in the cases referred to in paragraph 9, to the coordinating competent authority to allow it to make comments” (Article 89(8)).
How EU reports go today. The regulation sends these reports through EUDAMED, whose vigilance module is not yet in use. Until it is mandatory, guidance from the Medical Device Coordination Group (MDCG), the group of member states’ representatives that the Commission chairs, says makers “must continue to use the national reporting processes as explained in MDCG 2021-1 Rev. 1 and MDCG 2022-12 for compliance with the vigilance provisions outlined in the Regulations” (MDCG 2023-3 Rev.2, question 21). MDCG 2021-1 Rev.1 says: “Manufacturers should report serious incidents and field safety corrective actions to the respective/relevant national vigilance systems.” The authority that evaluates an FSCA is that of “the Member State(s) in which the FSCA is being or is to be undertaken”, and the one where the maker or its authorised representative has its registered place of business “must always be informed of the FSCA” (MDCG 2023-3 Rev.2, question 20). The same guidance says: “The manufacturer must allow 48 hours (equivalent to two weekdays) for receipt of comment on the draft FSN, unless the nature of the FSCA dictates a shorter timescale e.g. in the case of a serious public health threat.” Each of these MDCG documents says its views “are not legally binding”.
What to do. Before you start, unless the action is urgent, send the FSCA report and the draft notice through the national vigilance system of each member state where the action takes place, and inform the authority where you or your authorised representative have your registered place of business. Allow 48 hours for comments on the draft notice. If you must act at once, act, then report.
Evidence to keep. The report and draft notice with the date you sent each and the authorities you sent them to; the comments you received; for an urgent action, the reason it could not wait.
Great Britain: regulation 44ZJ of the Medical Devices Regulations 2002
Regulation 44ZJ(1) sets three steps “before taking any field safety corrective action”, unless the action is urgent. The manufacturer must:
- (a) produce a risk assessment of the proposed FSCA, and
- (b) submit to the Secretary of State
- (i) an initial report on the proposed action, and
- (ii) the proposed field safety notice setting out the details in paragraph (6).
Then “the manufacturer must implement the FSCA as soon as possible and monitor its progress” (44ZJ(3)). The urgent exception:
A manufacturer may submit an initial report and a copy of the field safety notice after taking the FSCA if the manufacturer believes the FSCA needs to be taken urgently.
The regulations name the Secretary of State. The MHRA, “the regulatory authority for the UK medical device market” in its own words, takes the reports. Its vigilance guidance says: “Manufacturers should submit reports to the MHRA relating to serious incidents, trends or FSCA for devices occurring in GB or NI via the MORE portal. The MHRA will not accept any reports received via other routes.” MORE is its Manufacturer’s Online Reporting Environment. On timing, the guidance says: “If you receive no response within 5 days of submitting the draft, you should send a copy of the final version of your FSN to MHRA (selecting “FSN status: Final FSN” on the form or XML) and circulate the FSN to your customers.” The MHRA’s separate guidance on field safety notices gives the wait as “5 working days”.
Northern Ireland follows the EU rules. The MHRA’s guidance on the 2024 regulations says devices there “must follow the post-market surveillance rules set out in EU MDR 2017/745 and EU IVDR 2017/746”. One report through MORE can cover an FSCA that affects both Great Britain and Northern Ireland.
When a maker acts outside Great Britain on the same model and does not take the same action in Great Britain, regulation 44ZK asks for a report that gives the reason. The MHRA’s vigilance guidance says makers “should notify the MHRA within 3 UK working days of the FSN being circulated”, outside MORE unless the action affects Northern Ireland.
Devices placed in Great Britain before June 2025. Part 4A covers devices placed on the market or put into service from the date it came into force (regulation 44ZD(1)). For earlier devices, the amending regulations keep the old rules: “The modifications made by Schedule 2A continue to apply, as if they had not been amended by regulation 5” (SI 2024/1368, regulation 6(1)). They sit in the annexes of Directive 93/42/EEC as Great Britain applies them (for active implantable devices and in vitro diagnostic devices, Directives 90/385/EEC and 98/79/EC): in Annex II, Section 3.1, the maker undertakes to review experience from its devices on the market, to apply any necessary corrective action, and to notify the Secretary of State of incidents “immediately on learning of them”. One such incident is “any technical or medical reason connected with the characteristics or performance of a device leading for the reasons referred to in subparagraph (i) to systematic recall of devices of the same type by the manufacturer”. The MHRA’s guidance places the detail in MEDDEV 2.12-1 rev 8, the Commission’s Guidelines on a Medical Devices Vigilance System of January 2013. For a model on the market both before and after the change, the same guidance says “two sets of PMS requirements will apply depending on when the device involved was placed on the market”, and adds: “As the new PMS requirements are generally more stringent than before, meeting these is expected to fulfil prior requirements, although each manufacturer should check this is the case for their medical devices.” It does not say how to report one action that covers devices from both periods; ask the MHRA.
What to do. Before you act, write the risk assessment and submit the initial report and the draft notice through MORE. Wait 5 working days for comments, which satisfies both of the MHRA’s pages, unless the action is urgent, then send the final notice to the MHRA and to customers. For a device placed before June 2025, notify the regulator immediately when you learn of an incident that leads to a recall. If one action covers devices placed before and after June 2025, meet the newer rules for all of them as well as the immediate notice for the older ones, and check that this meets the earlier rules, as the MHRA’s guidance asks.
Evidence to keep. The risk assessment; the initial report and draft notice with the MORE submission date; any comments you received; for an urgent action, the reason it could not wait; for each device, the date you placed it on the market.
Serious incident reports run on their own deadlines
In Great Britain, a serious incident report must give “consideration of whether any field safety corrective action is required to prevent or reduce the risk of a further serious incident” (regulation 44ZH(2)(g)). The incident report has its own deadlines. In the US, a maker reports within “30 calendar days” of becoming aware that a device may have caused or contributed to a death or serious injury, or has malfunctioned in a way likely to do so if it recurred (803.50(a)), and within “5 work days” when an event needs remedial action to prevent “an unreasonable risk of substantial harm to the public health” (803.53(a)) or the FDA has asked in writing for 5-day reports (803.53(b)). In the EU and Great Britain, it is due immediately once the maker has established a causal link with its device, or that one is reasonably possible, and at the latest within 15 days of becoming aware of the incident, 10 days for a death or an unanticipated serious deterioration in health, and 2 days for a serious public health threat (Article 87(3) to (5); regulation 44ZH(3) to (5)).
What the report to the regulator must contain
The US. Section 806.10(c) lists 13 items. They include the device’s names, intended use and marketing status; its UDI (unique device identifier) or model, lot or serial numbers; “A description of the event(s) giving rise to the information reported and the corrective or removal actions that have been, and are expected to be taken”; any illness or injury, with medical device report numbers; how many devices the action covers; every consignee in and outside the US, with dates and quantities; and “A copy of all communications regarding the correction or removal”. Where an item is not ready, the report says why, and when you expect to send it (806.10(c)(13)). The FDA recommends its fillable Form FDA 5072 for reports sent by email.
Great Britain. Regulation 44ZJ(2) sets six items:
- (a) the manufacturer’s name and contact details;
- (b) the UK responsible person’s name and contact details (if there is one);
- (c) a description of the devices, including any unique device identifiers;
- (d) a description of the FSCA and its proposed implementation;
- (e) the reason why the FSCA is required and the justification for the manufacturer’s chosen FSCA, based on the conclusions of the risk assessment produced under paragraph (1)(a);
- (f) the number of devices placed on the market or put into service in Great Britain and the estimated number of users affected.
The report goes on the FSCA report form in MORE. Since 16 October 2025, reports for Great Britain use the GB data schema: the MHRA allowed the old one “until the 16 of October 2025”, then withdrew that guidance because “the technical implementation period has now concluded”.
The EU. Article 87 lists no contents for the report, and Article 91 lets the Commission set “standard structured forms” by implementing acts. Until EUDAMED’s vigilance module is mandatory, MDCG 2021-1 Rev.1 says: “The current FSCA form should be used (the additional information required under the MDR may be added to the general comments section of the form).”
What to do. Keep one report pack that holds every item each market asks for: device identifiers, quantities per market, consignee lists, the risk assessment, the description of the action and copies of every communication. For the EU, fill in the FSCA report form that the European Commission publishes on its PMSV reporting forms page (version 2.11), and add what the regulation asks for in its general comments section.
Evidence to keep. The report pack for each action, with the version you sent to each regulator.
What the field safety notice or recall communication must say
The EU. Article 89(8) sets the content:
The field safety notice shall allow the correct identification of the device or devices involved, in particular by including the relevant UDIs, and the correct identification, in particular, by including the SRN, if already issued, of the manufacturer that has undertaken the field safety corrective action. The field safety notice shall explain, in a clear manner, without understating the level of risk, the reasons for the field safety corrective action with reference to the device malfunction and associated risks for patients, users or other persons, and shall clearly indicate all the actions to be taken by users.
The SRN is the single registration number a competent authority issues to each maker (Article 31(2)). The notice goes out in the official EU language or languages that each member state sets, with the same content everywhere unless a member state’s situation justifies a difference (Article 89(8)).
Great Britain. Regulation 44ZJ(6) says the field safety notice must:
- (a) identify the devices involved and include any unique device identifiers in a searchable format within the notice;
- (b) explain the reasons for the FSCA with reference to the risks to any person;
- (c) describe all actions to be taken by users in response.
The manufacturer “must take all reasonable steps to ensure the field safety notice is sent to users of the device” (44ZJ(5)). The MHRA’s guidance on field safety notices adds detail: a company letterhead, English, and “a clear title, with “Urgent FIELD SAFETY NOTICE” followed by the commercial name of the affected product, an FSCA identifier (for example, date or FSCA reference number) and the type of action”. It also asks for a UK contact point and an acknowledgement form, and rules out wording that would “play down the level of risk in an inappropriate manner”.
The US. Section 7.49 is guidance. It says a recall communication conveys:
- (1) That the product in question is subject to a recall.
- (2) That further distribution or use of any remaining product should cease immediately.
- (3) Where appropriate, that the direct account should in turn notify its customers who received the product about the recall.
- (4) Instructions regarding what to do with the product.
It should identify the product down to lot or serial numbers, explain the reason and the hazard, give specific instructions and offer a ready way to reply (7.49(c)). It “should not contain irrelevant qualifications, promotional materials, or any other statement that may detract from the message” (7.49(c)(2)).
What to do. Write one notice template that meets all three: device names with UDIs, models and lot or serial numbers in searchable text; the problem and the risk to patients and users, stated plainly; every action users must take, with timelines; a reply or acknowledgement form; and your contact point for each market.
Evidence to keep. Each notice as sent, in each language; the distribution list; every acknowledgement received.
After the action: final reports, status reports and records
Great Britain. After the action, “the manufacturer must submit a final report to the Secretary of State setting out the outcome of the action and including evidence to demonstrate its effectiveness” (44ZJ(7)). On request, the manufacturer provides the risk assessment and evidence of progress “within 3 working days of any such request” (44ZJ(8)). On that evidence, the MHRA’s vigilance guidance says: “A read receipt, automated response or proof of delivery is not a suitable method to demonstrate that the required action has been taken.”
The US. The recall guidance asks for recall status reports, “generally the reporting interval will be between 2 and 4 weeks” (7.53(a)), until the FDA ends the recall (7.55). For corrections and removals that Part 806 does not require you to report, you keep a record with the “Justification for not reporting the correction or removal action to FDA, which shall contain conclusions and any followups, and be reviewed and evaluated by a designated person” (806.20(b)(4)). You keep it “for a period of 2 years beyond the expected life of the device” (806.20(c)).
The EU. The current FSCA form offers three report types: “Initial report”, “Follow-up report” and “Final report”. The competent authority evaluates the action. Article 89(3) tells it to “evaluate the adequacy of the field safety corrective action envisaged or undertaken by the manufacturer and the need for, and kind of, any other corrective action”.
What to do. Track every consignee until they confirm the action, chase the ones who do not reply, and close each action with a final report that shows how many users confirmed it.
Evidence to keep. Acknowledgements and follow-ups per consignee; status reports; the final report; and for every unreported US correction or removal, the signed justification.
What changed in Great Britain, the US and the EU in 2025 and 2026
- Great Britain, June 2025. Part 4A of the Medical Devices Regulations 2002, the post-market surveillance rules, came into force. The MHRA gives the date as 16 June 2025; legislation.gov.uk records Part 4A as in force from 17 June 2025.
- Great Britain, 16 October 2025. Reports for Great Britain moved to the GB data schema in MORE.
- The US, 29 September 2025. The FDA’s device centre widened its Early Alerts: it “will now issue Early Alerts for potentially high-risk removals or corrections for all medical devices”. An alert can come before the agency decides whether the action meets the definition of a recall.
- The EU, 28 May 2026. Four EUDAMED modules became mandatory, among them actor registration and UDI and device registration. The vigilance and post-market surveillance module is “in development”, with no period of voluntary use before it becomes mandatory. Under Article 123(3)(d), the duties in Articles 87 and 88 that relate to the electronic system apply six months after the notice that the system works appears in the Official Journal.
What to do. If you sell in Great Britain, record for each device whether you placed it on the market before or after Part 4A came into force, because the rules differ. For the EU, plan the switch to EUDAMED reporting for the six months after the vigilance notice.
Evidence to keep. A dated note of the rules each device follows in each market, kept with the FSCA procedure.
What a late or missing report means in the US, the EU and Great Britain
The US. Part 806 carries out section 519(g) of the Federal Food, Drug, and Cosmetic Act (806.1(a)), which the US Code prints as 21 U.S.C. 360i(g). A device is misbranded if there was “a failure or refusal” to “furnish any material or information required by or under section 360i of this title respecting the device” (21 U.S.C. 352(t)). The Act also lists that failure among its prohibited acts (21 U.S.C. 331(q)(1)(B)).
The EU. The regulation leaves penalties to each member state: “The penalties provided for shall be effective, proportionate, and dissuasive” (Article 113). Where a device presents an unacceptable risk and the maker’s corrective action falls short, the competent authorities “shall take all appropriate measures to prohibit or restrict the making available of the device on their national market, to withdraw the device from that market or to recall it” (Article 95(4)).
Great Britain. The Medical Devices Regulations 2002 count as safety regulations under the Consumer Protection Act 1987 “for all purposes relating to enforcement (whether by criminal proceedings, notices or otherwise)” (regulation 61(1)). Section 12 of that Act sets the offences for breaching safety regulations. One is to fail “without reasonable cause” to give information that safety regulations require (section 12(4)), and the penalty on summary conviction is up to six months’ imprisonment, a fine, or both (section 12(5)). Neither the 2002 Regulations nor the Act names this offence for a missed FSCA report; whether it applies is a question for legal advice.
What to do. Log the date you start each action and the date you file each report in each market. Have a designated person review every decision not to report (806.20(b)(4)).
Evidence to keep. That log, with the reviewer’s name and the date on each decision.
One procedure that meets the US, EU and UK deadlines
If you start the action yourself and answer the regulators’ queries quickly, the FDA and the MHRA have less reason to take measures of their own. The US recall policy calls a recall “an alternative to a Food and Drug Administration-initiated court action for removing or correcting violative, distributed products” (7.40(a)), and says seizure or other court action “is indicated” in cases such as “when a firm refuses to undertake a recall requested by the Food and Drug Administration” (7.40(c)). In Great Britain, the MHRA’s guidance on field safety notices says: “We expect manufacturers to reply quickly to queries about FSCAs. Delayed replies increase the likelihood of the MHRA publishing separate advice to the health service in the interests of protecting public health. It may also lead to the MHRA initiating legal compliance action.” A US report is also no admission: the maker “need not admit, and may deny” that it shows the device caused or contributed to a death or serious injury (806.10(e)).
The triggers overlap: each regime acts on a risk to health from a device already on the market. The deadlines differ, and one order of work meets all three:
- Assess. Decide whether you need to act, file any serious incident report by its own deadline, record the health hazard evaluation and the risk assessment, and list every market where you sell the same model.
- Draft. Draft the report and the field safety notice, with every item each market asks for.
- Report in the EU and Great Britain. Before you start, unless the action is urgent, send the report and the draft notice to the MHRA through MORE, and through the national vigilance system of each member state concerned. In the EU, this includes an action outside the EU on a device also on the EU market, unless its reason is limited to the device there.
- Wait for comments. Allow 48 hours for EU comments and 5 working days for comments in Great Britain, then send the final notice through MORE.
- Act. Start the action, send the notice to users, and notify the FDA of a recall when you start it.
- Report in the US. File the Part 806 report within 10 working days of the start, and amend it within 10 working days of extending the action.
- Report to Great Britain for actions elsewhere. Report an action taken elsewhere to the MHRA within 3 UK working days of its notice going out, if you do not take it in Great Britain.
- Close. Track acknowledgements, send US status reports at the interval the FDA sets, answer a request from the regulator in Great Britain within 3 working days, and close with a final report.
What to do. Write this order into one FSCA and recall procedure, with an owner for each step and each market’s deadline beside it.
Evidence to keep. The procedure, and for each action a dated record that shows each step done.
Questions about field safety corrective actions and recalls
What is a field safety corrective action?
It is the action a device maker takes “for technical or medical reasons to prevent or reduce the risk of a serious incident in relation to a device made available on the market”, in the words of the EU Medical Device Regulation, Article 2(68). Great Britain’s definition, in regulation 44ZC of the Medical Devices Regulations 2002, covers devices already placed on the market or put into service. A recall, a modification, a software update and new advice to users can each be one.
What is a field safety notice?
It is the maker’s message to users about a field safety corrective action. In the EU and Great Britain it must identify the devices, including their UDIs, explain the risk and set out every action users must take (Article 89(8); regulation 44ZJ(6)). The MHRA asks for a title that starts “Urgent FIELD SAFETY NOTICE”, then gives the product name, a reference and the type of action.
Is a recall the same as a field safety corrective action?
A recall is one kind. The EU defines a recall as “any measure aimed at achieving the return of a device that has already been made available to the end user” (Article 2(62)), and the MHRA lists a recall first among its examples of FSCAs. In the US, the FDA uses “recall” for a correction or removal of a device it considers in breach of the law and would take legal action over, such as seizure (21 CFR 7.3(g)).
What are the FDA’s medical device recall classes?
The agency assigns each recall a class by its health hazard (21 CFR 7.3(m)). Class I: “a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death”. Class II: use or exposure “may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote”. Class III: use or exposure “is not likely to cause adverse health consequences”.
How long do you have to report under 21 CFR 806?
Ten working days from the start of the correction or removal (806.10(b)), and the same for an amendment that extends the action to more lots or batches (806.10(d)). The report covers actions started to reduce a risk to health, or to remedy a violation that may present one, unless you have reported them under Part 803 or Part 1004 or they are exempt under 806.1(b).
Can the FDA order a medical device recall?
Yes. Under 21 CFR Part 810, if the agency finds “a reasonable probability that a device intended for human use would cause serious, adverse health consequences or death”, it may order the firm to stop distributing the device and to notify health professionals and device user facilities (810.10(a)). It may then amend the order to require a recall (810.13). The FDA’s own page says it “has rarely needed to require a medical device recall”.
What makes a medical device recall urgent?
In the US, the FDA’s guidance says the recall letter and envelope “should be also marked: “urgent” for class I and class II recalls and, when appropriate, for class III recalls” (7.49(b)). In Great Britain, the MHRA asks for “Urgent FIELD SAFETY NOTICE” in the title of every notice. Urgency also changes the order of work in the EU and Great Britain: a maker that must act at once may act first and report after (Article 87(8); regulation 44ZJ(4)).
Do regulators publish recalls and field safety notices?
Yes. The FDA lists each new recall in its weekly Enforcement Report (7.50) and posts actions in its Medical Device Recall Database. The MHRA publishes weekly lists of field safety notices that affect the UK. In the EU, MDCG 2021-1 Rev.1 says the competent authorities “should make these field safety notices publicly available/accessible to the public in accordance with their national legislation”, until the maker can enter each notice in EUDAMED, “through which that notice shall be accessible to the public” (Article 89(8)).
More guides
- 21 CFR Part 11 · EU Annex 1121 CFR Part 11 compliance: the requirements and EU Annex 11 comparedRead the guide
- 21 CFR Part 860 · EU MDR Annex VIIIMedical device classification: class 1, 2 and 3 under the FDA, EU and MHRA rulesRead the guide
- 21 CFR Part 820 · ISO 13485ISO 13485 and the FDA QMSR (21 CFR 820): the requirements comparedRead the guide
Sources
United States
- 21 CFR Part 806, Medical Devices; Reports of Corrections and Removals, eCFR, up to date as of 17 November 2026: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-806
- 21 CFR Part 7, section 7.3 and Subpart C (recalls): https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-7
- 21 CFR Part 803, Medical Device Reporting, sections 803.50 and 803.53: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-803
- 21 CFR Part 810, Medical Device Recall Authority: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-810
- 21 U.S.C. 352, misbranded drugs and devices, United States Code, 2024 edition, govinfo: https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec352.htm
- 21 U.S.C. 331, prohibited acts, United States Code, 2024 edition, govinfo: https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapIII-sec331.htm
- 21 U.S.C. 360i, records and reports on devices, United States Code, 2024 edition, govinfo: https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec360i.htm
- FDA, Recalls, Corrections and Removals (Devices): https://www.fda.gov/medical-devices/postmarket-requirements-devices/recalls-corrections-and-removals-devices
- FDA, What is a Medical Device Recall?: https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/what-medical-device-recall
- FDA, What is an Early Alert?: https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/what-early-alert
European Union
- Regulation (EU) 2017/745 on medical devices, consolidated text of 9 November 2026, EUR-Lex: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02017R0745-20261109
- MDCG 2023-3 Rev.2, Questions and Answers on vigilance terms and concepts, January 2025: https://health.ec.europa.eu/document/download/af1433fd-ed64-4c53-abc7-612a7f16f976_en?filename=mdcg_2023-3_en.pdf
- MDCG 2021-1 Rev.1, Guidance on harmonised administrative practices and alternative technical solutions until EUDAMED is fully functional, May 2021: https://health.ec.europa.eu/system/files/2021-05/2021-1_guidance-administrative-practices_en_0.pdf
- European Commission, PMSV reporting forms, with the FSCA report form (version 2.11): https://health.ec.europa.eu/medical-devices-sector/new-regulations/guidance-mdcg-endorsed-documents-and-other-guidance/pmsv-reporting-forms_en
- European Commission, FSCA report form: https://health.ec.europa.eu/document/download/6fd3a214-89de-4f16-a7d2-746271068cc7_en?filename=md_new-reg_fsca-report_en.pdf
- European Commission, EUDAMED overview: https://health.ec.europa.eu/medical-devices-eudamed/overview_en
Great Britain
- The Medical Devices Regulations 2002 (SI 2002/618), Part 4A, regulations 44ZC, 44ZD, 44ZH, 44ZJ and 44ZK, legislation.gov.uk: https://www.legislation.gov.uk/uksi/2002/618/part/4A
- The Medical Devices Regulations 2002, regulation 61, legislation.gov.uk: https://www.legislation.gov.uk/uksi/2002/618/regulation/61
- The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 (SI 2024/1368), regulation 6, legislation.gov.uk: https://www.legislation.gov.uk/uksi/2024/1368/made
- Directive 93/42/EEC, Annex II, legislation.gov.uk: https://www.legislation.gov.uk/eudr/1993/42/annex/II
- Directive 90/385/EEC, Annex 2, legislation.gov.uk: https://www.legislation.gov.uk/eudr/1990/385/annex/2
- Directive 98/79/EC, Annex III, legislation.gov.uk: https://www.legislation.gov.uk/eudr/1998/79/annex/III
- European Commission, MEDDEV 2.12-1 rev 8, Guidelines on a Medical Devices Vigilance System, January 2013: https://ec.europa.eu/docsroom/documents/32305/attachments/1/translations
- Consumer Protection Act 1987, section 12, legislation.gov.uk: https://www.legislation.gov.uk/ukpga/1987/43/section/12
- MHRA, Medical devices: post-market surveillance requirements: https://www.gov.uk/government/publications/medical-devices-post-market-surveillance-requirements
- MHRA, Field safety notices: guidance for manufacturers: https://www.gov.uk/guidance/effective-field-safety-notices-fsns-guidance-for-manufacturers-of-medical-devices
- MHRA, MORE implementation, with the GB schema guide and the guidance withdrawn on 16 October 2025: https://www.gov.uk/government/publications/more-implementation
- MHRA, First major overhaul of medical device regulation comes into force across Great Britain, 16 June 2025: https://www.gov.uk/government/news/first-major-overhaul-of-medical-device-regulation-comes-into-force-across-great-britain
Published recalls and field safety notices
- FDA, Medical Device Recall Database: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm
- FDA, Enforcement Reports: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/enforcement-reports
- MHRA, Alerts, recalls and safety information, field safety notices: https://www.gov.uk/drug-device-alerts?alert_type%5B%5D=field-safety-notices
General information, not legal advice. We read every source above in November 2026 and check them each month; the date at the top of the page shows the last review.